Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

Icotrokinra is a first-in-class oral peptide drug that selectively inhibits the IL-23 receptor, disrupting IL-23 signaling ...

Among adults with obesity who lost weight after following a low-calorie diet, weight-loss maintenance with exercise was ...

The EMA’s recommendation marks a key step toward expanding treatment access for patients with psoriasis, psoriatic arthritis, ...

DelveInsight’s “Atopic Dermatitis Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 120+ ...

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,12,13 ...

Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.

Immunotherapy has transformed the treatment of cancer, yet many patients do not have response or lasting benefit. Strategies ...

A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the ...

High doses of temtokibart — including 600 mg, 450 mg, and 300 mg — contributed to significant improvements in disease severity in patients with AD.

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best healthcare penny stocks to buy now. On September 8, 2025, ImmunityBio Inc.

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to ...